Mats Wahlstrom bought $47k of TLSI
director, owner at TriSalus Life Sciences, Inc.. 10,727 shares at an average of $4.39, traded Nov 20, 2024, filed Nov 22, 2024.
Score components
- +15RoleDirector
- +6Trade size$47k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.6%, 3m +27.4%, 6m +22.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027587, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | POpen-market purchase Common Stock | +2,040 | $4.16 | $8,486 | 2,040 | Nov 22, 2024 |
| Nov 21, 2024 | POpen-market purchase Common Stock | +8,687 | $4.44 | $39k | 10,727 | Nov 22, 2024 |
Related signals
Other insiders at TriSalus Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $1,299 296 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,427 325 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $1,387 316 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $25k 4,764 shares | -4% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jodi Devlin Chief of Clinical Operations | $25k 4,764 shares | -8% | |
| 36Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $34k 6,597 shares | -9% | |
| 41Moderate | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $45k 8,704 shares | -10% | |
| 15Weak | TLSIsell TriSalus Life Sciences, Inc. | Bryan F. Cox CHIEF SCIENTIFIC & MANUFACT. | $1,394 314 shares | -0% | |
| 20Weak | TLSIbuy TriSalus Life Sciences, Inc. | Frankenius Equity AB owner | $250k 62,972 shares | +1% | |
| 30Weak | TLSIsell TriSalus Life Sciences, Inc. | Arjun JJ Desai director | $111k 30,000 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.